Neena Patil Sells 1,200 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total transaction of $289,128.00. Following the transaction, the executive vice president directly owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $240.83 on Wednesday. The firm has a fifty day moving average price of $249.27 and a 200 day moving average price of $224.90. Jazz Pharmaceuticals PLC has a 1 year low of $124.47 and a 1 year high of $266.38. The stock has a market cap of $15.63 billion, a P/E ratio of 16.61, a P/E/G ratio of 0.22 and a beta of 0.36. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. During the same quarter in the prior year, the business posted ($8.25) EPS. The firm’s quarterly revenue was up 15.5% compared to the same quarter last year. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current year.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz completed its $820 million acquisition of Actio Biosciences. The deal adds ABS-1230, a potential first-in-class precision therapy for KCNT1-related epilepsy, to Jazz’s neuroscience pipeline. The transaction strengthens the company’s focus on rare epilepsy and could create a future growth driver if clinical development succeeds. Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
• Positive Sentiment: Jazz is exploring additional uses for Ziihera in oncology. The company reportedly plans trials evaluating the therapy in breast, colorectal and lung cancers. Expanding Ziihera into multiple tumor types could increase its commercial opportunity, although the programs remain dependent on clinical results and regulatory approvals. Jazz Pharmaceuticals Eyes Ziihera Trials
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, Jazz management discussed the company’s business and development pipeline. The transcript did not identify a major change to guidance or a new near-term catalyst, leaving the update broadly informational for investors. Jazz Pharmaceuticals Morgan Stanley Conference Transcript
• Negative Sentiment: The Actio transaction requires a sizeable $820 million upfront payment. While the acquisition improves Jazz’s long-term pipeline, the cash commitment increases near-term execution risk and may prompt investor concerns about capital allocation, especially before ABS-1230 demonstrates clinical efficacy.
• Negative Sentiment: An executive insider sale provided a modest negative signal. EVP Neena Patil sold 1,200 shares worth approximately $289,000. However, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, limiting its value as an indicator of management’s current outlook. Jazz Pharmaceuticals Insider Sale

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft boosted their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Royal Bank Of Canada set a $299.00 target price on Jazz Pharmaceuticals in a research note on Friday, August 28th. Finally, JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $286.72.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of the company. USA Financial Formulas purchased a new position in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Ameritas Advisory Services LLC acquired a new stake in shares of Jazz Pharmaceuticals in the second quarter worth approximately $47,000. Leonteq Securities AG purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $50,000. Westpac Banking Corp acquired a new position in Jazz Pharmaceuticals in the 1st quarter valued at $51,000. Finally, Root Financial Partners LLC raised its stake in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 89 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.